Heron Therapeutics(US:HRTX) Prnewswireยท2025-08-08 11:45Core Insights - Heron Therapeutics reported strong financial results for Q2 2025, with net revenue of $37.2 million and year-to-date revenue of $76.1 million, reaffirming its 2025 net revenue guidance of $153 million to $163 million [7][3] - The company achieved record year-to-date adjusted EBITDA of $7.9 million, raising its full-year adjusted EBITDA guidance from $4.0 million - $12.0 million to $9.0 million - $13.0 million [7][3] - The company is focused on expanding its core products, particularly ZYNRELEF and APONVIE, with significant unit demand growth reported [8][7] Financial Performance - Q2 2025 net revenue increased by 3.3% compared to Q2 2024, with total net revenue reaching $37.2 million [9] - Year-to-date net revenue for the first half of 2025 was $76.1 million, reflecting a 7.7% increase from $70.7 million in the same period of 2024 [10] - The Acute Care franchise saw a year-over-year revenue growth of 55.5% in Q2 2025 and 70.5% for the first half of 2025 [8] Product Updates - ZYNRELEF unit demand grew by 6.3% in Q2 2025 compared to Q1 2025, with plans for expanded commercial initiatives in Q3 2025 [8] - APONVIE unit demand increased by 19% in Q2 2025 compared to Q1 2025, supported by increased adoption in hospital systems [8] - The Centers for Medicare and Medicaid Services granted a permanent J-code for ZYNRELEF, effective October 1, 2025, which will streamline reimbursement processes [8] Debt and Financial Flexibility - The company completed a comprehensive capital restructuring, reducing total debt from $175 million to $145 million and extending debt maturities to at least 2030 [7] - As of June 30, 2025, cash, cash equivalents, and short-term investments totaled $40.6 million [8] Management Commentary - The CEO emphasized the company's commitment to executing strategic priorities and driving sustainable growth, reflecting the dedication of the team and the growing demand for innovative solutions [2]